Talazoparib plus enzalutamide approved in EU for mCRPC
The combination is approved for the treatment of patients with metastatic castration-resistant prostate cancer, regardless of mutation status.
Advanced technology, novel techniques drive use of radiation in prostate cancer
“Radiation therapy continues to expand its role, especially if you start talking about [patients with] the ultra high–risk [prostate cancer] or node-positive [disease] and beyond,” says Daniel Spratt, MD.
FDA allows marketing of genetic test for predisposition to several cancers, including prostate
The Invitae Common Hereditary Cancers Panel utilizes DNA taken from a blood sample to identify the presence of variants in 47 genes linked to an increased risk of developing certain cancers.
NCCN adds flotufolastat F 18 to prostate cancer guidelines
Flotufolastat F 18 is now included in the NCCN prostate cancer guideline recommendations for all the same categories as the other PSMA-PET imaging agents approved by the FDA.
Researchers look to ADCs and radiotherapeutics to advance renal cell carcinoma care
Investigations of treatment regimens featuring antibody-drug conjugates or radiotherapeutics are part of the ongoing wave of research in renal cell carcinoma, according to Rana R. McKay, MD.
FDA approves flotufolastat F 18 for PSMA-PET imaging in prostate cancer
The approval of flotufolastat F 18 (formerly 18F-rhPSMA-7.3) in prostate cancer is based on findings from the phase 3 SPOTLIGHT and LIGHTHOUSE trials.
Darolutamide linked to lower discontinuation and progression rates in nmCRPC
Data from the retrospective DEAR study linked darolutamide to lower rates of discontinuation and progression to metastatic disease vs enzalutamide and apalutamide in patients with nonmetastatic castration-resistant prostate cancer.
Combination talazoparib/enza bolsters rPFS in men with metastatic CRPC
Data showed that treatment with talazoparib plus enzalutamide resulted in a 37% reduction in the risk of progression or death as assessed by blinded independent central review.
FDA accepts application for 18F-rhPSMA-7.3 for prostate cancer
The application is supported by findings from a phase 1 trial and two phase 3 trials, SPOTLIGHT and LIGHTHOUSE.
Combination nivolumab/ipilimumab after nivolumab monotherapy shows benefit in advanced RCC
Data showed that nivolumab followed by nivolumab/ipilimumab resulted in an overall response rate of 34%.
Reader reproducibility high with 18F-rhPSMA-7.3 image interpretation in prostate cancer
“These findings from the SPOTLIGHT study showed high inter-reader and intra-reader agreement for interpretation of 18F-rhPSMA-7.3 PET/CT scans in the setting of biochemical recurrence,” said Phillip Kuo, MD, PhD.
Novel PET imaging agent 18F-rhPSMA-7.3 increases upstaging in recurrent prostate cancer
Compared with baseline conventional imaging, PET imaging with 18F-rhPSMA-7.3 frequently led to post-scan disease upstaging in men with prostate cancer recurrence, according to the latest data from the phase 3 SPOTLIGHT trial.
Dr. Dreicer on optimizing treatment for patients with mCSPC
According to Dreicer, standard treatment in this setting for most patients should include androgen deprivation therapy (ADT) in combination with 1 or 2 other agents vs ADT therapy alone.
Lenvatinib falls short as add-on to pembrolizumab in urothelial carcinoma
The addition of lenvatinib to pembrolizumab did not improve overall survival in patients with advanced urothelial carcinoma.
2 Commerce Drive Cranbury, NJ 08512